EU approves Seroquel for prevention and recurrence of bipolar disorder
This article was originally published in Scrip
Executive Summary
The EU has approved supplemental applications for AstraZeneca's Seroquel (quetiapine fumarate) and once-daily Seroquel XR for the prevention of recurrence of bipolar disorder under the European Mutual Recognition Procedure, which was sponsored by the Netherlands. The company will now seek local approvals from member states as it moves towards a European launch.